Related Experiment Video
Updated: Jun 10, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Controlling the Mdm2-Mdmx-p53 Circuit.
David L Waning1, Jason A Lehman, Christopher N Batuello
1Herman B Wells Center for Pediatric Research, 980 West Walnut, Walther Hall R3-C548, Indianapolis, IN 46202, USA.
The p53 tumor suppressor protein is crucial for genome integrity. Phosphorylation of p53, Mdm2, and Mdmx stabilizes p53, offering a therapeutic strategy, but kinase inhibitors require careful consideration.
Area of Science:
- Molecular Biology
- Cancer Biology
- Genetics
Background:
- The p53 tumor suppressor is vital for genomic stability, inducing cell cycle arrest or apoptosis.
- Mdm2 and Mdmx inactivate p53 by inhibiting transcription and promoting degradation.
- Post-translational modifications, particularly phosphorylation, stabilize and activate p53 under genotoxic stress.
Purpose of the Study:
- To review key phosphorylation events of p53, Mdm2, and Mdmx in response to DNA damage.
- To discuss the implications of these modifications for p53 stability and activity.
- To evaluate therapeutic strategies targeting the Mdm2-Mdmx-p53 axis in cancer.
Main Methods:
- Literature review focusing on phosphorylation events in the p53 pathway.
- Analysis of studies investigating p53, Mdm2, and Mdmx regulation by DNA damage.
- Examination of the therapeutic potential and risks of modulating the Mdm2-Mdmx-p53 axis.
Main Results:
- Phosphorylation of p53, Mdm2, and Mdmx is critical for p53 stabilization and activation following genotoxic stress.
- Modulating Mdm2 and Mdmx signaling presents a promising therapeutic strategy for reactivating wild-type p53 in tumors.
- Targeting the Mdm2-Mdmx-p53 axis with kinase inhibitors requires careful consideration due to potential p53 inactivation.
Conclusions:
- Phosphorylation plays a central role in the p53 response to DNA damage, influencing its stability and tumor suppressor function.
- Targeting Mdm2 and Mdmx offers a viable therapeutic avenue for p53 reactivation in cancer treatment.
- Development of kinase inhibitors must carefully balance therapeutic benefits against the risk of unintended p53 destabilization.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

